Drug Approval | February 21, 2025
GSK's Nucala application for COPD accepted for review in China
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Offers affordable, high-quality solutions for diabetes care
Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
Approval is based on positive data from the Phase 3 ECHELON-3 trial
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Branded formulation business continues to perform well across domestic and export markets
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
Subscribe To Our Newsletter & Stay Updated
